Some Shift Attention In Rx Price Debate To Supply Chain; Others Call It A Diversion

Some drug makers and their allies are trying to shift the debate over drug prices away from drug makers toward companies along the supply chain, such as pharmacy benefit managers, but others say it's a diversion. They note most drugs that have experienced price spikes in recent years don't have competition and pharmacy benefit managers can't negotiate rebates for monopoly products. “You’re seeing drug makers pointing the finger at middle men more and more,” said Peter Maybarduk, director of Public...